You have accessJournal of UrologyBladder Cancer: Invasive II1 Apr 2015MP58-07 TUMOR PD-L1 AND LYMPHOCYTIC INFILTRATE FOXP3 STATUS IN NON-MUSCLE INVASIVE UROTHELIAL CARCINOMA OF BLADDER (NMIBC) Gunes Guner, Maria Angelica Mendoza Rodriguez, Alexander Baras, Jen-Jane Liu, Sheila Friedrich Faraj, Nilda Gonzales-Roibon, Noah M Hahn, Charles Drake, Trinity J. Bivalacqua, Janis Taube, Katayoon Rezaei, and George Netto Gunes GunerGunes Guner More articles by this author , Maria Angelica Mendoza RodriguezMaria Angelica Mendoza Rodriguez More articles by this author , Alexander BarasAlexander Baras More articles by this author , Jen-Jane LiuJen-Jane Liu More articles by this author , Sheila Friedrich FarajSheila Friedrich Faraj More articles by this author , Nilda Gonzales-RoibonNilda Gonzales-Roibon More articles by this author , Noah M HahnNoah M Hahn More articles by this author , Charles DrakeCharles Drake More articles by this author , Trinity J. BivalacquaTrinity J. Bivalacqua More articles by this author , Janis TaubeJanis Taube More articles by this author , Katayoon RezaeiKatayoon Rezaei More articles by this author , and George NettoGeorge Netto More articles by this author View All Author Informationhttps://doi.org/10.1016/j.juro.2015.02.2146AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookTwitterLinked InEmail INTRODUCTION AND OBJECTIVES Programmed death ligand 1 (PD-L1) is a cell surface glycoprotein that inhibits T cells and plays a crucial role in suppressing immune response. PD-L1 expression has been associated with worse prognosis in several malignancies including advanced stage in urothelial carcinoma. We evaluated PD-L1 in NMIBC in relationship with tumor infiltrating CD8+ density and proliferation and FOXP3 expression. METHODS 3 TMAs were constructed from 165 TURB specimens of 52 bladder cancer patients treated at George Washington University (1998-2008). Paired FFPE tumor and benign samples were spotted 3-6 times each. Immunohistochemistry was performed using PD-L1 (Cell-Signalling, E1L3N, 1:100), FOXP3 (eBioscience, 236A/E7, 1:250), CD8 (Thermo Scientific, SP16, 1:900), Ki67 (Invitrogen/Zymed 7B11, 1:900). Percentage of membranous PD-L1 expression in tumor and tumor inflammatory reaction, number of FOXP3+ cells/hpf and CD8+ T cells/hpf were calculated in each spot. Fraction of CD8+/Ki67+ T cells and tumor Ki67 proliferation index were also assessed. Associations between markers and stage progression were evaluated. Effect of BCG Rx on expression status of above markers was assessed. RESULTS 5/20 pT1 cases progressed to pT2 (median follow-up: 382 days). 8 cases with no progression during at least 1 year F/U were used for comparison. Using 5% as cutoff, high tumor PD-L1 expression was associated with increased risk of progression (66% vs 30%, RR: 2.2). In contrast, high PD-L1 expression in the tumor associated inflammatory reaction correlated with lower risk of progression (14% vs 66%, RR 0.21). The trend was not statistically significant most likely due to small number of events. Using ¡Ý15 cells /hpf as a cutoff, high density of FOXP3+ lymphocytes was associated with increased likelihood for progression (60% vs 33%; RR 1.8). As expected, Higher tumor Ki67 (¡Ý30%) was also associated with progression (50% vs 20%; RR 2.5). 12 pts had evaluable pre and post BCG biopsies. Significantly higher number of intratumoral FOXP3+ and CD8+/Ki67+ lymphocytes was seen in post BCG compared to pre BCG biopsies (p=0.02 and p= 0.054 respectively). CONCLUSIONS Our findings of increased intratumoral FOXP3+ & CD8+/Ki67+ lymphocytes post BCG and the suggested association of increased FOXP3+ lymphocytes and tumoral PD-L1 expression with higher risk of progression warrant further investigation in relation to outcome in a larger cohort of NMIBC pts. © 2015 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 193Issue 4SApril 2015Page: e723-e724 Advertisement Copyright & Permissions© 2015 by American Urological Association Education and Research, Inc.MetricsAuthor Information Gunes Guner More articles by this author Maria Angelica Mendoza Rodriguez More articles by this author Alexander Baras More articles by this author Jen-Jane Liu More articles by this author Sheila Friedrich Faraj More articles by this author Nilda Gonzales-Roibon More articles by this author Noah M Hahn More articles by this author Charles Drake More articles by this author Trinity J. Bivalacqua More articles by this author Janis Taube More articles by this author Katayoon Rezaei More articles by this author George Netto More articles by this author Expand All Advertisement Advertisement PDF downloadLoading ...